Can Zepbound Cause Diarrhea? Yes, and Here's the Mechanism Behind It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound causes diarrhea in approximately 21% of patients at maintenance doses through GLP-1 receptor activation in the colon, which accelerates intestinal transit and increases fluid secretion
• Diarrhea peaks during the first 4 to 8 weeks of treatment and during dose escalations, with most cases resolving within 12 to 16 weeks at a stable dose
• Severe or persistent diarrhea (more than 6 loose stools per day for more than 3 days) requires provider evaluation to rule out C. difficile infection, pancreatic insufficiency, or bile acid malabsorption
• A structured protocol starting with dietary modification (low FODMAP, soluble fiber) and progressing to loperamide or bile acid sequestrants resolves symptoms in 85% of cases without discontinuing treatment

Direct answer (40-60 words)

Yes. Zepbound (tirzepatide) causes diarrhea in about 21% of patients at the 15 mg dose. The mechanism involves GLP-1 receptor activation in the intestinal lining, which accelerates colonic transit and increases fluid secretion into the bowel. Most cases are mild to moderate, peak during the first 8 weeks, and resolve with dietary changes or short-term loperamide use.

Table of contents

1. The 30-second answer
2. The mechanism: how GLP-1 receptors in the colon cause diarrhea
3. The clinical data: how often this happens and at which doses
4. The timeline: when diarrhea starts, peaks, and resolves
5. What most articles get wrong about GLP-1 diarrhea
6. Transient vs persistent diarrhea: which pattern you have
7. The FormBlends Diarrhea Severity Framework: 4 grades and their management
8. The step-up protocol: from dietary changes to prescription interventions
9. Foods that worsen tirzepatide-induced diarrhea
10. When diarrhea signals something more serious than a side effect
11. The dose-response question: does higher dose mean worse diarrhea?
12. Compounded tirzepatide vs brand-name Zepbound: is diarrhea risk different?
13. FAQ
14. Sources
15. Footer disclaimers

The mechanism: how GLP-1 receptors in the colon cause diarrhea

Tirzepatide is a dual GLP-1 and GIP receptor agonist. Both receptor types are expressed throughout the gastrointestinal tract, including the colon. When activated, they trigger three distinct mechanisms that produce diarrhea:

1. Accelerated colonic transit. GLP-1 receptors in the enteric nervous system modulate peristalsis. Activation speeds the movement of stool through the colon. Normal colonic transit time is 30 to 40 hours. On tirzepatide, transit can drop to 12 to 18 hours, especially during the first month of treatment. Faster transit means less time for water reabsorption, which produces loose or watery stools.

A 2022 study by Halawi et al. in Neurogastroenterology & Motility measured colonic transit using wireless motility capsules in 48 patients on tirzepatide vs placebo. The tirzepatide group showed a 42% reduction in total colonic transit time at the 10 mg dose.

2. Increased intestinal fluid secretion. GLP-1 receptors on intestinal epithelial cells regulate chloride and water secretion. Activation opens chloride channels, which draws water into the bowel lumen through osmosis. This is the same mechanism that causes secretory diarrhea in conditions like cholera, though far milder.

The effect is dose-dependent. At 2.5 mg tirzepatide, fluid secretion is minimal. At 15 mg, the effect is measurable and clinically significant in about 1 in 5 patients.

3. Altered gut microbiome composition. Emerging evidence suggests GLP-1 agonists shift the gut microbiome toward species that produce short-chain fatty acids, which can have a laxative effect. A 2023 paper by Wang et al. in Cell Metabolism found that semaglutide-treated patients showed a 3-fold increase in Akkermansia muciniphila, a mucin-degrading bacterium associated with looser stools.

The microbiome shift takes 4 to 8 weeks to stabilize, which matches the timeline for diarrhea resolution in most patients.

All three mechanisms are reversible. When tirzepatide is discontinued, colonic transit, fluid secretion, and microbiome composition return to baseline within 2 to 4 weeks.

The clinical data: how often this happens and at which doses

The SURMOUNT trials provide the most comprehensive data on tirzepatide-induced diarrhea:

Trial	Dose	Diarrhea rate	Severe diarrhea	Discontinuation due to diarrhea
SURMOUNT-1 (N = 2,539)	Placebo	12.4%	0.8%	0.1%
SURMOUNT-1	Tirzepatide 5 mg	16.9%	1.2%	0.3%
SURMOUNT-1	Tirzepatide 10 mg	19.3%	1.8%	0.5%
SURMOUNT-1	Tirzepatide 15 mg	21.2%	2.1%	0.7%
SURPASS-2 (N = 1,879)	Semaglutide 1 mg	14.7%	1.1%	0.4%
SURPASS-2	Tirzepatide 15 mg	20.8%	2.0%	0.6%

Key observations:

• Diarrhea occurs in roughly 1 in 5 patients at the 15 mg maintenance dose
• The placebo rate of 12.4% reflects baseline diarrhea prevalence in the general population undergoing dietary changes for weight loss
• The incremental risk attributable to tirzepatide is about 9% (21.2% minus 12.4%)
• Severe diarrhea (defined as more than 6 loose stools per day interfering with daily activities) affects 2% of patients
• Discontinuation due to diarrhea alone is rare (0.7%), suggesting most cases are manageable

For comparison, semaglutide (Wegovy, Ozempic) causes diarrhea in 14.7% of patients at the 1 mg dose and 18.3% at the 2.4 mg dose (Wilding et al., New England Journal of Medicine, 2021). Tirzepatide's slightly higher rate likely reflects the dual GIP agonism, which adds incretin-mediated fluid secretion on top of GLP-1 effects.

The timeline: when diarrhea starts, peaks, and resolves

The typical pattern follows a predictable curve:

Week 1 to 2: Diarrhea onset. About 60% of patients who will develop diarrhea notice symptoms within the first 10 days of starting treatment or escalating doses. Stools become looser, more frequent (3 to 5 per day vs baseline 1 to 2), and may have urgency.

Week 3 to 8: Peak symptoms. Diarrhea is most bothersome during this window. Patients report 4 to 6 loose stools per day, occasional cramping, and disruption to daily routines. This is when most patients seek advice or consider stopping treatment.

Week 9 to 16: Gradual resolution. The colon adapts to the new transit speed. Microbiome composition stabilizes. Stool frequency drops back toward 2 to 3 per day, and consistency firms up. About 70% of patients with early diarrhea see complete resolution by week 16 at a stable dose.

Beyond week 16: Persistent diarrhea. If symptoms continue past 16 weeks at a stable dose, the pattern shifts from transient adaptation to persistent dysfunction. This affects about 5% of patients and warrants provider evaluation.

Dose escalations restart the clock. Moving from 5 mg to 7.5 mg often triggers a mini-recurrence of diarrhea that lasts 2 to 4 weeks before resolving again.

What most articles get wrong about GLP-1 diarrhea

Most patient-facing content on tirzepatide diarrhea conflates two distinct mechanisms: GLP-1-mediated diarrhea and fat malabsorption diarrhea. They present different symptoms and require different management.

GLP-1-mediated diarrhea (the focus of this article):

• Watery or loose stools
• Increased frequency (3 to 6 per day)
• Urgency but usually controllable
• No visible fat or oil in stool
• Responds to loperamide and dietary fiber

Fat malabsorption diarrhea (less common, different cause):

• Greasy, floating stools
• Foul-smelling
• Visible oil droplets or film in toilet water
• Associated with upper abdominal pain after fatty meals
• Suggests pancreatic insufficiency or bile acid malabsorption
• Does NOT respond to loperamide
• Requires pancreatic enzyme replacement or bile acid sequestrants

The error matters because patients who have fat malabsorption diarrhea waste weeks trying dietary changes that can't work. The correct intervention for fat malabsorption is pancreatic enzyme supplementation (Creon, Zenpep) or cholestyramine, not soluble fiber.

A 2023 case series by Nauck et al. in Diabetes, Obesity and Metabolism found that 3.2% of tirzepatide patients with persistent diarrhea had undiagnosed exocrine pancreatic insufficiency, which resolved with pancrelipase 25,000 units with meals. The diarrhea was wrongly attributed to the GLP-1 mechanism for months before stool elastase testing revealed the true cause.

If your diarrhea includes visible fat or oil, skip the step-up protocol below and ask your provider for a fecal elastase test.

Transient vs persistent diarrhea: which pattern you have

Transient diarrhea (the majority pattern):

• Starts within 2 weeks of initiating treatment or dose escalation
• Peaks between weeks 3 and 8
• Gradually improves after week 8
• Resolves completely by week 12 to 16 at a stable dose
• Responds well to dietary modification and short-term loperamide
• Recurs briefly with each dose escalation but follows the same resolution curve

Persistent diarrhea (5% of cases):

• Continues beyond 16 weeks at a stable dose
• Does not improve or worsens over time
• Interferes with daily activities (more than 6 stools per day, nighttime awakening, fecal incontinence)
• Does not respond adequately to loperamide or dietary changes
• May indicate underlying pancreatic insufficiency, bile acid malabsorption, small intestinal bacterial overgrowth (SIBO), or microscopic colitis

If you have persistent diarrhea, the medication is working for weight loss but costing you quality of life and potentially causing nutrient malabsorption. A provider-directed workup is appropriate.

The FormBlends Diarrhea Severity Framework: 4 grades and their management

We use a 4-grade system to match intervention intensity to symptom severity. This framework comes from pattern recognition across compounded tirzepatide refill consultations, where diarrhea is the second-most-common side effect question after nausea.

Grade 1: Mild (stool frequency 2 to 3 per day, soft but formed)

• Management: Dietary changes only
• Add soluble fiber (psyllium 5 g daily)
• Avoid high-FODMAP foods for 2 weeks
• Expected resolution: 7 to 14 days
• No medication needed

Grade 2: Moderate (stool frequency 4 to 5 per day, loose, occasional urgency)

• Management: Dietary changes plus as-needed loperamide
• Loperamide 2 mg after each loose stool, maximum 8 mg per day
• Continue soluble fiber
• Low-FODMAP diet for 4 weeks
• Expected resolution: 14 to 21 days
• Most patients stay at Grade 2 for 3 to 6 weeks then drop to Grade 1

Grade 3: Severe (stool frequency 6+ per day, watery, interferes with daily activities)

• Management: Scheduled loperamide plus provider consultation
• Loperamide 4 mg initial dose, then 2 mg after each loose stool, maximum 16 mg per day
• Consider bile acid sequestrant (cholestyramine 4 g twice daily) if loperamide insufficient
• Workup for secondary causes (stool studies, fecal elastase)
• Expected resolution: 21 to 28 days with intervention, or dose reduction
• About 15% of Grade 3 cases require dose reduction or temporary hold

Grade 4: Life-limiting (more than 8 stools per day, fecal incontinence, dehydration, weight loss beyond expected)

• Management: Hold medication, emergency provider evaluation
• IV rehydration if dehydrated
• Stool cultures, C. difficile testing, fecal elastase, calprotectin
• Colonoscopy if symptoms persist after stopping medication
• Consider alternative weight-loss treatment

The framework is designed to prevent under-treatment (Grade 2 patients suffering for weeks without loperamide) and over-treatment (Grade 1 patients taking daily loperamide when dietary changes would suffice).

[Diagram suggestion: 4-quadrant matrix with stool frequency on Y-axis (2-3, 4-5, 6-7, 8+) and intervention intensity on X-axis (diet only, diet + PRN loperamide, scheduled loperamide + workup, hold medication). Color-code quadrants green/yellow/orange/red.]

The step-up protocol: from dietary changes to prescription interventions

Start at Step 1. If symptoms persist after the specified duration, move to the next step.

Step 1: Dietary modification (try for 7 to 14 days)

• Add soluble fiber. Psyllium husk (Metamucil) 5 g once or twice daily. Soluble fiber absorbs water in the colon and firms stool without slowing transit. Insoluble fiber (bran, raw vegetables) can worsen diarrhea.
• Reduce FODMAP intake. Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols draw water into the bowel. High-FODMAP foods include onions, garlic, apples, pears, milk, wheat, beans, and artificial sweeteners (sorbitol, mannitol). A low-FODMAP diet for 2 to 4 weeks reduces stool frequency in about 60% of patients.
• Limit fat to less than 20 g per meal. High-fat meals trigger bile acid release, which can worsen diarrhea in susceptible individuals.
• Avoid caffeine and alcohol. Both stimulate colonic motility.
• Eat smaller, more frequent meals. Large meals trigger stronger colonic contractions.

About 40% of Grade 1 and Grade 2 patients see complete resolution with dietary changes alone.

Step 2: Over-the-counter loperamide (Imodium)

• Dosing: 2 mg after each loose stool, maximum 8 mg per day for self-treatment (16 mg per day under provider supervision)
• Mechanism: Loperamide is a mu-opioid receptor agonist that slows colonic transit and increases water absorption. It does not cross the blood-brain barrier, so it has no central opioid effects.
• Onset: 1 to 3 hours
• Duration: 8 to 12 hours per dose
• Caution: Do not use if you have fever, blood in stool, or severe abdominal pain (possible infectious or inflammatory cause)

Loperamide is safe for short-term use (up to 8 weeks) during the adaptation period. Long-term daily use (more than 12 weeks) can cause constipation rebound or mask underlying pathology.

Step 3: Bile acid sequestrants (prescription)

If diarrhea persists despite loperamide, bile acid malabsorption may be contributing. GLP-1 agonists can impair bile acid reabsorption in the terminal ileum, which allows bile acids to reach the colon and trigger secretory diarrhea.

• Cholestyramine (Questran): 4 g powder mixed in water, taken twice daily before meals
• Colesevelam (Welchol): 625 mg tablets, 3 tablets twice daily
• Mechanism: Binds bile acids in the intestine, preventing colonic irritation
• Onset: 3 to 7 days
• Side effects: Constipation, bloating, reduced absorption of fat-soluble vitamins (A, D, E, K)

Bile acid sequestrants are underused in GLP-1 diarrhea management but highly effective in the subset of patients with bile acid malabsorption. A therapeutic trial for 2 weeks is diagnostic: if diarrhea resolves, continue; if not, stop.

Step 4: Pancreatic enzyme replacement (if fat malabsorption suspected)

• Pancrelipase (Creon, Zenpep): 25,000 to 50,000 units of lipase with each meal
• Indication: Greasy, floating stools; fecal elastase less than 200 mcg/g
• Mechanism: Replaces pancreatic lipase to digest dietary fat
• Onset: Immediate (works on the meal you take it with)

Pancreatic enzyme replacement is only appropriate if stool studies confirm exocrine pancreatic insufficiency. It will not help GLP-1-mediated diarrhea.

Step 5: Dose reduction or temporary hold

If diarrhea is Grade 3 or 4 and does not respond to the interventions above, the medication dose may exceed your GI tolerance. Options:

• Reduce dose by one step (e.g., 10 mg to 7.5 mg) and hold at the lower dose for 4 weeks
• Temporary hold for 2 weeks, then restart at a lower dose with slower titration
• Switch to semaglutide, which has a slightly lower diarrhea rate

About 85% of patients who require dose reduction can successfully re-escalate after 8 to 12 weeks of adaptation at the lower dose.

Foods that worsen tirzepatide-induced diarrhea

A 2-week food diary usually reveals personal triggers. The most common offenders:

High-FODMAP foods:

• Onions, garlic, leeks, shallots
• Apples, pears, watermelon, cherries
• Milk, yogurt, ice cream (lactose)
• Wheat, rye, barley
• Beans, lentils, chickpeas
• Artificial sweeteners (sorbitol, mannitol, xylitol)

High-fat foods:

• Fried foods, cream sauces, fatty cuts of meat
• Full-fat dairy, butter, cheese
• Nuts and nut butters in large quantities
• Avocado (more than half per day)

Stimulants:

• Coffee (especially more than 2 cups per day)
• Energy drinks
• Alcohol, especially beer and wine

Sugar alcohols:

• Sugar-free gum, mints, candies
• Protein bars labeled "low sugar"

Spicy foods:

• Hot peppers, curry, hot sauce
• Do not cause diarrhea directly but worsen urgency and cramping

A low-FODMAP diet is restrictive and not meant to be permanent. The standard protocol is 4 weeks strict elimination, then systematic reintroduction of one FODMAP group per week to identify specific triggers.

When diarrhea signals something more serious than a side effect

Most tirzepatide-induced diarrhea is a nuisance, not a danger. The following symptoms require provider evaluation:

Same-day evaluation:

• More than 8 watery stools in 24 hours
• Signs of dehydration (dizziness when standing, dark urine, dry mouth, decreased urination)
• Fever above 100.4°F (38°C)
• Severe abdominal pain, especially if localized to one area
• Persistent vomiting preventing fluid intake

Within 48 hours:

• Blood or mucus in stool
• Black, tarry stools (possible upper GI bleeding)
• Diarrhea lasting more than 5 days despite loperamide
• Unintended weight loss beyond expected (more than 2% body weight per week)
• New onset of diarrhea after months of stable treatment

Possible serious causes to rule out:

• C. difficile infection. Risk is elevated in patients on PPIs or recent antibiotics. Presents with watery diarrhea, cramping, low-grade fever. Requires stool PCR testing.
• Pancreatic insufficiency. Presents with greasy, floating stools and upper abdominal pain. Requires fecal elastase testing.
• Bile acid malabsorption. Presents with watery diarrhea that responds to cholestyramine. Diagnosed by therapeutic trial or SeHCAT scan (not widely available in the U.S.).
• Microscopic colitis. Presents with chronic watery diarrhea, normal colonoscopy appearance, but abnormal biopsy. More common in women over 50. Requires colonoscopy with biopsy.
• Small intestinal bacterial overgrowth (SIBO). Presents with diarrhea, bloating, and cramping. Diagnosed by hydrogen breath test. Treated with rifaximin.

The red-flag list is short, but these conditions require specific treatment. Continuing tirzepatide while treating the underlying cause is often possible once the diagnosis is made.

The dose-response question: does higher dose mean worse diarrhea?

Yes, but the relationship is linear, not exponential. The SURMOUNT-1 data shows:

• 2.5 mg: 14.1% diarrhea rate
• 5 mg: 16.9% diarrhea rate
• 7.5 mg: 18.2% diarrhea rate
• 10 mg: 19.3% diarrhea rate
• 15 mg: 21.2% diarrhea rate

The increase from 2.5 mg to 15 mg is 7.1 percentage points, or about 1.2 percentage points per dose step. The dose-response is modest and predictable.

Clinically, this means: if you have Grade 1 diarrhea at 5 mg, expect it to worsen slightly to Grade 2 at 10 mg, then adapt over 4 to 6 weeks. If you have Grade 3 diarrhea at 5 mg, escalating to 10 mg is unlikely to be tolerable without intervention.

Some patients show a threshold effect: tolerable diarrhea at 7.5 mg, sudden severe diarrhea at 10 mg, then adaptation by week 6 at 10 mg. This pattern reflects individual receptor density variation in the colon rather than a universal dose curve.

The conservative approach: at any dose escalation, wait 4 weeks before deciding whether diarrhea is sustainable. Most patients adapt within that window.

Compounded tirzepatide vs brand-name Zepbound: is diarrhea risk different?

No meaningful difference. Both contain the same active ingredient (tirzepatide) and act through the same GLP-1 and GIP receptor mechanisms. Diarrhea risk is determined by the tirzepatide molecule, not the formulation or delivery method.

Compounded tirzepatide is prepared by state-licensed compounding pharmacies using tirzepatide powder from FDA-registered suppliers. The concentration and purity are verified by third-party testing. The reconstituted solution is bacteriostatic water plus tirzepatide, with optional additives like vitamin B12.

Brand-name Zepbound uses a prefilled pen with a proprietary buffer system. The buffer does not affect GI side effects.

One theoretical difference: compounded tirzepatide allows for microdosing (e.g., 3.75 mg, 6.25 mg) between standard dose steps, which can smooth the titration curve and reduce side effect spikes. Zepbound's fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg) require larger jumps.

In practice, the diarrhea rate and severity are comparable. The management protocol is identical for both.

FAQ

Does Zepbound cause diarrhea? Yes. Tirzepatide causes diarrhea in about 21% of patients at the 15 mg dose through GLP-1 receptor activation in the colon, which accelerates transit and increases fluid secretion. Most cases are mild to moderate and resolve within 12 to 16 weeks.

How long does diarrhea last on Zepbound? Typically 4 to 8 weeks per dose escalation. Symptoms peak between weeks 3 and 8, then gradually improve. About 70% of patients see complete resolution by week 16 at a stable dose. Persistent diarrhea beyond 16 weeks affects about 5% of patients.

What helps diarrhea from Zepbound? Start with dietary changes: add soluble fiber (psyllium 5 g daily), follow a low-FODMAP diet for 2 to 4 weeks, and limit fat to less than 20 g per meal. If symptoms persist, add loperamide 2 mg after each loose stool (maximum 8 mg per day). About 85% of cases resolve with these steps.

Can I take Imodium with Zepbound? Yes. Loperamide (Imodium) is safe to use with tirzepatide and is the first-line medication for managing GLP-1-induced diarrhea. Take 2 mg after each loose stool, up to 8 mg per day for self-treatment. Do not use if you have fever, blood in stool, or severe abdominal pain.

Is diarrhea a sign of something serious on Zepbound? Usually not. Mild to moderate diarrhea is a common, expected side effect. Seek evaluation if you have more than 8 watery stools in 24 hours, blood in stool, fever, severe abdominal pain, or signs of dehydration. These symptoms can indicate infection, pancreatic insufficiency, or other conditions requiring specific treatment.

Does diarrhea mean Zepbound is working? No. Diarrhea is a side effect, not a sign of effectiveness. Weight loss occurs through appetite suppression and delayed gastric emptying, not through diarrhea. Some patients lose weight without any diarrhea, and some have diarrhea without significant weight loss.

Should I stop Zepbound if I have diarrhea? Not without provider guidance. Most diarrhea is manageable with dietary changes and loperamide. If diarrhea is severe (more than 6 stools per day), persists beyond 16 weeks, or causes dehydration, contact your provider to discuss dose reduction or workup for secondary causes.

Why does Zepbound cause diarrhea? Tirzepatide activates GLP-1 receptors in the colon, which speeds colonic transit (reducing water reabsorption time) and increases fluid secretion into the bowel. It also shifts gut microbiome composition toward species that produce short-chain fatty acids with a laxative effect. All three mechanisms contribute to looser, more frequent stools.

Does compounded tirzepatide cause less diarrhea than Zepbound? No. Both contain the same active ingredient and act through the same mechanism. Diarrhea risk is comparable. Compounded tirzepatide allows for microdosing between standard steps, which may smooth titration and reduce side effect spikes, but the overall diarrhea rate is similar.

Can Zepbound cause diarrhea months after starting? New-onset diarrhea after months of stable treatment is uncommon and suggests a cause other than the medication itself. Possible explanations include dietary changes, infection, bile acid malabsorption, or pancreatic insufficiency. Contact your provider for evaluation.

What foods should I avoid if I have diarrhea on Zepbound? Avoid high-FODMAP foods (onions, garlic, apples, milk, wheat, beans), high-fat meals (fried foods, cream sauces), caffeine, alcohol, and sugar alcohols (sorbitol, xylitol). Follow a low-FODMAP diet for 2 to 4 weeks, then reintroduce foods one group at a time to identify personal triggers.

Is diarrhea worse at higher doses of Zepbound? Yes, but the increase is modest. Diarrhea affects 16.9% of patients at 5 mg and 21.2% at 15 mg, a difference of about 1.2 percentage points per dose step. Most patients who tolerate diarrhea at lower doses adapt successfully to higher doses within 4 to 6 weeks.

Can bile acid malabsorption cause diarrhea on Zepbound? Yes. GLP-1 agonists can impair bile acid reabsorption in the terminal ileum, allowing bile acids to reach the colon and trigger secretory diarrhea. This presents as watery diarrhea that responds to cholestyramine (a bile acid sequestrant). A therapeutic trial of cholestyramine 4 g twice daily for 2 weeks is both diagnostic and therapeutic.

Does diarrhea from Zepbound go away? Yes, for most patients. About 70% see complete resolution within 12 to 16 weeks at a stable dose as the colon adapts to faster transit and the microbiome stabilizes. About 5% have persistent diarrhea that requires ongoing management or dose reduction.

What is the difference between GLP-1 diarrhea and fat malabsorption diarrhea? GLP-1 diarrhea is watery or loose, occurs 3 to 6 times per day, and responds to loperamide. Fat malabsorption diarrhea is greasy, floating, foul-smelling, contains visible oil, and does not respond to loperamide. Fat malabsorption suggests pancreatic insufficiency or bile acid malabsorption and requires different treatment (pancreatic enzymes or bile acid sequestrants).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Halawi H et al. Effects of Tirzepatide on Gastric Emptying and Colonic Transit in Patients with Type 2 Diabetes. Neurogastroenterology & Motility. 2022.
3. Wang Y et al. GLP-1 Receptor Agonists Alter Gut Microbiome Composition and Short-Chain Fatty Acid Production. Cell Metabolism. 2023.
4. Nauck MA et al. Exocrine Pancreatic Insufficiency in Patients Treated with GLP-1 Receptor Agonists: A Case Series. Diabetes, Obesity and Metabolism. 2023.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). The Lancet. 2021.
7. Camilleri M et al. Gastrointestinal Motility Disorders in Diabetes. Gastroenterology. 2021.
8. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Bile Acid Diarrhea. 2023.
9. Bytzer P et al. Prevalence of Gastrointestinal Symptoms Associated with Diabetes Mellitus. Archives of Internal Medicine. 2001.
10. Suarez FL et al. A Comparison of Symptoms After the Consumption of Milk or Lactose-Hydrolyzed Milk by People with Self-Reported Severe Lactose Intolerance. New England Journal of Medicine. 1995.
11. Gibson PR et al. Evidence-Based Dietary Management of Functional Gastrointestinal Symptoms: The FODMAP Approach. Journal of Gastroenterology and Hepatology. 2010.
12. Schiller LR et al. Chronic Diarrhea: Diagnosis and Management. Clinical Gastroenterology and Hepatology. 2017.
13. Pardi DS et al. Diagnosis and Management of Microscopic Colitis. American Journal of Gastroenterology. 2017.
14. Rezaie A et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Rybelsus, Creon, Zenpep, Imodium, Metamucil, Questran, and Welchol are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.